Why does coronary artery dissection (CAD) cause functional mitral regurgitation (MR)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Coronary artery dissection can cause functional mitral regurgitation primarily through ischemic injury to the left ventricular myocardium and papillary muscles, leading to reduced closing force on the leaflets and systolic tethering of the leaflets into the LV, as described in the basic principles of the echocardiographic evaluation of mitral regurgitation 1. This occurs when the dissection compromises blood flow to the heart muscle, resulting in myocardial ischemia or infarction in the territory supplied by the affected vessel. If this ischemia affects the posterolateral wall of the left ventricle where papillary muscles are located, it can cause papillary muscle dysfunction or rupture. Some key points to consider include:

  • The papillary muscles are critical for normal mitral valve function as they connect to the mitral valve leaflets via chordae tendineae, and when damaged, they cannot properly support the mitral valve during systole, leading to incomplete closure of the valve and subsequent regurgitation of blood back into the left atrium.
  • Ischemia can cause regional wall motion abnormalities and left ventricular remodeling, which alter the geometry of the mitral valve apparatus, further contributing to functional mitral regurgitation, as noted in the guidelines for the diagnosis and treatment of acute and chronic heart failure 1.
  • The use of echocardiography in acute cardiovascular care is essential in evaluating the severity of mitral regurgitation and guiding treatment decisions, as recommended by the European Association of Cardiovascular Imaging and the Acute Cardiovascular Care Association 1. The most effective treatment approach for functional mitral regurgitation caused by coronary artery dissection involves optimizing medical treatment, considering surgical repair or replacement, and evaluating the need for percutaneous edge-to-edge repair in high-risk patients, as outlined in the guidelines for the diagnosis and treatment of acute and chronic heart failure 1.

From the Research

Coronary Artery Dissection and Functional Mitral Regurgitation

  • Coronary artery dissection can lead to left ventricular dysfunction, which is a known cause of functional mitral regurgitation (MR) 2, 3.
  • Functional MR occurs when there is a dysbalance between closing and opening forces on the mitral leaflets due to reduced left ventricular contractility, geometric distortion of the subvalvular apparatus, and global dilatation of the left ventricle and the mitral annulus 2.
  • Ischemic cardiomyopathy, resulting from coronary artery dissection, can cause left ventricular dysfunction and subsequent congestive heart failure (CHF) and ischemic mitral regurgitation (IMR) 3.
  • The underlying pathology of IMR is attributed to a dysfunctional left ventricle, and even mild IMR has been shown to be harmful to CHF patients 3.

Mechanism of Functional Mitral Regurgitation

  • Functional MR can be classified into two types: ventricular functional MR (VFMR) and atrial functional MR (AFMR) 4.
  • VFMR is caused by left ventricular dilatation and/or systolic dysfunction, while AFMR is caused by mitral annular dilatation due to left atrial dilatation 4.
  • Coronary artery dissection can lead to VFMR by causing left ventricular dysfunction and dilatation 2, 3.

Clinical Implications

  • Functional MR has a negative impact on both symptoms and prognosis in patients with CHF and systolic left ventricular dysfunction 2.
  • Treatment options for functional MR include surgical correction, cardiac resynchronization therapy (CRT), and transcatheter mitral valve repair 2, 3, 5.
  • The choice of treatment depends on the severity of left ventricular dysfunction and the presence of other comorbidities 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ischemic Mitral Regurgitation: Current Understanding and Surgical Options.

Indian journal of thoracic and cardiovascular surgery, 2020

Research

Outcomes of transcatheter mitral valve repair for secondary mitral regurgitation by severity of left ventricular dysfunction.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2021

Related Questions

What is the best algorithm for referring patients for MitraClip (percutaneous mitral valve repair) as a non-invasive cardiologist (Non-Invasive Cardiology)?
How does the Valsalva (forced exhalation) maneuver affect mitral regurgitation seen on echocardiogram (echo)?
What is the management plan for a patient with a 2D echo result showing concentric left ventricular (LV) remodeling, preserved contractility and systolic function, mitral valve sclerosis, and mild mitral regurgitation?
Should a 63-year-old male with Heart Failure with Reduced Ejection Fraction (HFrEF) (Diagnosed in 2023, Ejection Fraction 15-20%, Non-Ischemic Cardiomyopathy (NICM), Left Ventricular End-Diastolic Diameter (LVEDD) 7.4cm), history of Cerebrovascular Accident (CVA) (Right Middle Cerebral Artery (R-MCA), Left Hemiplegia, 2023), Chronic Kidney Disease (CKD) (Stage 3b), Hypertension (HTN), Hyperlipidemia (HLD), Right Lower Lobe (RLL) nodule, and malnutrition, who has undergone multiple hospitalizations for Acute Decompensated Heart Failure (ADHF) and is currently on Carvedilol (Beta Blocker) 3.125 mg twice daily, Jardiance (Empagliflozin) 10 mg daily, Valsartan (Angiotensin II Receptor Blocker) 20 mg twice daily, Spironolactone (Aldosterone Antagonist) 12.5 mg daily, and Atorvastatin (HMG-CoA Reductase Inhibitor) 80 mg daily, with significant Left Ventricular (LV) dysfunction, severe Mitral Regurgitation (MR), and unable to tolerate further Guideline-Directed Medical Therapy (GDMT) due to hypotension, be considered for a MitraClip procedure?
What is the recommended management for a 77-year-old female with normal left ventricular (LV) systolic function, mild mitral valve regurgitation, and grade I diastolic dysfunction?
What is the best course of treatment for a 56-year-old female patient with Attention Deficit Hyperactivity Disorder (ADHD) and depression, currently taking Ritalin (methylphenidate) and Pristiq (desvenlafaxine), with complaints of insomnia and dissatisfaction with Trazodone (trazodone) due to hangover effects, and who is also taking Clonazepam (clonazepam) 2mg as needed?
What Pre-Exposure Prophylaxis (PrEP) medications can I take in Europe?
What are the most common causes of postoperative Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)?
Is there an association between Neuroleptic Malignant Syndrome (NMS) and Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)?
What is the normal blood pressure for a 96-year-old female?
What is the referral for an isometric tremor (action tremor)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.